News

Panel backs approval of alirocumab, biologic injectable lipid-lowering drug


 

AT AN FDA ADVISORY COMMITTEE MEETING

References

Pages

Recommended Reading

Alogliptin CV risk acceptable, FDA panel agrees
MDedge Internal Medicine
Testosterone therapy has neutral cardiovascular effects
MDedge Internal Medicine
TRACE-RA: Statin therapy may prevent CVD in RA
MDedge Internal Medicine
ILC: Statins linked to better outcomes in hepatitis C cirrhosis
MDedge Internal Medicine
Biologics cut cholesterol, may reduce mortality
MDedge Internal Medicine
Asymptomatic carotid stenosis and central sleep apnea linked
MDedge Internal Medicine
Chest pain: Risks of evaluation may outweigh benefits
MDedge Internal Medicine
AUA: Testosterone may not deserve its reputation as a cardiovascular culprit
MDedge Internal Medicine
Traditional diagnostic criteria miss OSA in coronary artery disease patients
MDedge Internal Medicine
FDA panel set to review two biologic lipid-lowering drugs for approval
MDedge Internal Medicine

Related Articles